Study details
Enrolling now
Safety and Efficacy of ONT01 in Lupus
Hospital for Special Surgery, New York
NCT IDNCT07107659ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
61
Study length
about 3.7 years
Ages
18+
Locations
1 site in NY
What this study is about
Researchers are testing the safety and effectiveness of a new drug called ONT01 for people with lupus nephritis or systemic lupus erythematosus. The trial will also evaluate if taking ONT01 along with other common lupus medications improves symptoms.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ONT01 is a small molecule CD11b modulator
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Adverse Events, Study Completion versus Withdrawal
Body systems
Immune